Low‐dose decitabine plus venetoclax is safe and effective as post‐transplant maintenance therapy for high‐risk acute myeloid leukemia and myelodysplastic syndromeYunxiong Wei, Mingfeng Zhao, Wenyi Lu et al.|Cancer Science|2021Cited by 71